Why the study?
Does adjuvant chemotherapy alter coagulation factors and platelet function in patients with Stage II breast cancer?
Does adjuvant chemotherapy alter coagulation factors and platelet function in patients with Stage II breast cancer?
Adjuvant chemotherapy in Stage II breast cancer patients induces a significant decrease in thrombin time and partial prothrombin time, suggesting a hypercoagulable state.
Answers are grounded in this paper and cite their sources.
Adjuvant chemotherapy may promote hypercoagulability in stage II breast cancer; leaves open need for prospective thrombotic risk studies.
An increased incidence of thromboembolic complications occurring in cancer patients during chemotherapy was recently reported. In view of this report, a study in 49 patients receiving adjuvant chemotherapy for Stage II breast cancer was begun in order to determine the effect of antineoplastic drugs on coagulation factors and platelet function. Among the coagulation factors, a significant decrease of thrombin time and partial prothrombin time was observed, whereas platelet function tests were unchanged. This finding suggests a trend towards hypercoagulability induced by chemotherapy. This effect should be considered when chemotherapy is employed in advanced cancer patients at high risk for thrombosis.
No takes yet. Share an insight, caveat, or question.
Canobbio et al. (1986) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: